161061-33-2

Upstream product

• 161061-34-3 1-(ethoxymethyl)-5-isopropyluracil 
• 1026065-34-8 1-Ethoxymethyl-6-(hydroxy-phenyl-methyl)-5-isopropyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one 
• 144410-21-9 1-(ethoxymethyl)-5-isopropyl-2-thiouracil 
• 100-52-7 benzaldehyde 

Downstream Products

• 1026714-30-6 6-benzyl-1-(ethoxymethyl)-5-isopropyl-3-(2-oxo-2-phenylethyl)pyrimidine-2,4(1H,3H)-dione 
• 1026720-95-5 6-Benzyl-5-isopropyl-1-(2-methoxy-ethyl)-3-(2-oxo-2-phenyl-ethyl)-1H-pyrimidine-2,4-dione 
• 1027144-85-9 6-Benzyl-1-butyl-5-isopropyl-3-(2-oxo-2-phenyl-ethyl)-1H-pyrimidine-2,4-dione 
• 165960-84-9 6-benzyl-5-isopropyl-3-(2-oxo-2-phenylethyl)pyrimidine-2,4(1H,3H)-dione 
• 149950-60-7 Emivirine 

Relevant academic research and scientific papers

ANTIVIRAL AGENTS

An antiviral agent against retroviruses exhibiting synergistic antiviral effect which comprises as active ingredients a 6-benzyl-1-ethoxy-methyl-5-substituted uracil derivative such as 6-benzyl-1-ethoxymethyl-5-isopropyluraci together with two or more sub

Synergistic antiviral compositions

Antiviral agents which comprises as active ingredients one or more 2',3'-dideoxyribonucleosides or phosphoric esters thereof and 6-benzyl-1-ethoxymethyl-5-substituted uracil derivative of the formula (I): STR1 wherein X is oxygen or sulfur atom; R1/

Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2- hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents

Several 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6- (phenylthio)thymine (1; HEPT) were synthesized and evaluated for their anti- HIV-1 activity. LDA (lithium diisopropylamide) lithiation of 5-ethyluracil derivatives 7 and 8 and subsequent reaction with an aryl aldehyde gave 6- (arylhydroxymethyl)-5-ethyluracil derivatives 9-12. 6-(Arylhydroxymethyl)-5- isopropyluracil derivatives 15-18 were prepared from the 5-isopropyl-2- thiouracil derivatives 13 and 14 by the above procedure following oxidative hydrolysis of the thione. Preparation of the target 5-alkyl-1-(alkoxymethyl)- 6-benzyluracil derivatives 27-34 was carried out by acetylation of 9-14 followed by Pd-catalyzed hydrogenolysis. The 1-butyl- (37 and 39) and 1-(2- methoxyethyl)- (38 and 40) 5-alkyl-6-benzyluracils were synthesized by 1- alkylation of the 3-phenacyl derivatives 35 and 36 with alkyl halides followed by deprotection of the 3-phenacyl group. Compounds synthesized in this study inhibited HIV-1 replication in MT-4 cells in the submicromolar to nanomolar concentration range. From this series of compounds, 6-benzyl-1- (ethoxymethyl)-5-isopropyluracil (33) was selected for clinical evaluation.